Buserelin

Buserelin (Suprefact/Suprecur) is a real, decades-old GnRH agonist — mechanistically identical to leuprolide and goserelin, and used in one of the original 1982 trials that helped establish the entire GnRH-agonist drug class — that has simply never been submitted for or granted FDA approval; our own reading of the timeline points to market timing rather than a documented safety concern.

Same drug class as leuprolide and goserelin

Buserelin is a synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH) — the same drug class as leuprolide, goserelin, triptorelin and nafarelin, already covered on this site. Like them, continuous stimulation of the GnRH receptor paradoxically shuts the receptor down, suppressing testosterone or estrogen production. Two substitutions to the natural GnRH sequence (a D-serine(tert-butyl) at position 6, and an ethylamide in place of the terminal glycinamide) make it roughly 20-170 times more potent than the natural hormone at first triggering LH and FSH release, before that suppression sets in.

One of the original trials that created this drug class

Developed by Hoechst AG (as HOE-766), buserelin was first introduced for medical use in West Germany in 1984 — a year before leuprolide's 1985 US approval and five years before goserelin's 1989 US approval, making it one of the very first GnRH agonists to reach any market. It was also used in one of the earliest human proof-of-concept studies for the entire class: a landmark 1982 trial out of Montreal gave buserelin to men with advanced prostate cancer and reported real tumor regression from a drug working entirely through hormonal suppression, not surgery (Tolis et al., Proc Natl Acad Sci USA 1982;79(5):1658-1662) — a finding that helped establish chemical castration via the GnRH receptor as a genuine alternative to orchiectomy, opening the door for the whole drug class that followed.

Why the US never got it

Despite that early role, buserelin was never submitted for FDA approval. No company statement or regulatory record explains why; the most plausible inference, based on timing alone rather than any documented reason, is market economics rather than a safety or efficacy concern — by the time a US filing might have followed, leuprolide (1985) and goserelin (1989) had already captured the American market for this drug class, leaving little commercial incentive to fund a separate FDA review for a third, largely interchangeable entrant. It remains approved and marketed today — as Suprefact (injection/depot, for prostate cancer) and Suprecur (nasal spray, for endometriosis and IVF long-protocol down-regulation) — across the UK, Ireland and other EU countries, Canada, and elsewhere, under Sanofi, Hoechst's eventual corporate successor.

A 2025 study puts a number on how rarely it's used in America

A 2025 pharmacovigilance study comparing five long-acting GnRH agonists using the FDA's own adverse-event database (FAERS) is a useful, indirect measure of exactly how small buserelin's US footprint is: of roughly 52,500 combined reports analyzed, leuprolide accounted for 43,683, goserelin 5,138, triptorelin 3,143 and histrelin 501 — against just 52 for buserelin (Chen et al., PLoS One 2025;20(7):e0327842, PMID 40644420). Those 52 reports most likely reflect Sanofi's global pharmacovigilance obligations feeding into the FDA's database rather than any real US prescribing, but the study did find buserelin's adverse-event signal genuinely differed from its stablemates: a higher proportion of gastrointestinal events than the other four, where histrelin instead stood out for psychiatric events.

Current status

Buserelin's real risks are the same class-wide ones already covered on this site's leuprolide and goserelin pages: an initial testosterone or estrogen "flare" at treatment start (disease flare occurs in under 10% of prostate-cancer patients per its UK and Canadian labeling, managed the same way — a short course of an anti-androgen), plus the longer-term bone-density and metabolic effects shared across the whole GnRH-agonist class. Current UK and Irish product licenses for Suprefact and Suprecur remain active as of this review; Canadian marketing status for the injectable/nasal forms could not be pinned down from public listings, which disagreed with each other — check directly with a pharmacist or Health Canada's own Drug Product Database rather than assume either way. We found no wellness or grey-market presence; this is a conventional, prescription-only hospital/clinic hormone therapy, not a research-chemical product.